We used clinical trial data to map some of the most promising drug startups to their stage of development in this pharma market landscape.
The pharmaceutical industry is seeing rapid development thanks to a handful of new promising technologies. The introduction of immunotherapy techniques such as CAR-T cell therapy along with cancer vaccines are advancing oncology while CRISPR is poised to bring genetic editing into every clinic.
While immunotherapy has received most of the press in the pharma community, well-funded startups also are working to cure neurodegenerative diseases such as Alzheimer’s, prevent blindness, halt the spread of infection, and treat chronic pain.
Large pharmaceutical corporates such as Novartis, Pfizer, and Celgene are responsible for many of the drugs used in hospitals today, but these large companies often seek to acquire smaller drug development startups that have already completed time-consuming research, and are now moving through clinical trials. As they complete the early stages of drug development, these startups shown below have raised just over $10B in equity funding in 2016 alone from investors including life science-focused VCs, pharmaceutical corporates, and tech giants alike.
